IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 1.55 (2012 - 2016).    Offical Sponser for International Conference in malaysia ,  https://www.icmhas.com/

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
PIPPHARMACON & IJPR 2018

PIPPHARMACON & IJPR 2018

Click to download
 

Article Detail

Label
Label
3D-Quantitative Structure Activity Relationship Study of Pyrazolothiazol-4-(5H)-One Derivatives as Epidermal Growth Factor Receptor Inhibitors

Author: DEEAPLI JAGDALE, MAHESH KHARATMOL, PRIYANAKA GANDHI, PRIYANKA GAIKWAD, NEHA NANDEDKAR
Abstract: Pyrazolothiazol-4-(5H)-one derivatives were synthesized and studied for in vitro anti-cancer activity on cell line MCF-7 which is known to over-express epidermal growth factor receptor (EGFR). EGFR is considered as a good target for chemotherapeutic intervention. Three-dimensional quantitative structure activity relationship (3D-QSAR) approach became very useful and largely widespread technique for ligand-based drug design. In this paper, an attempt was made to develop a 3D-QSAR study on a series of pyrazolothiazol-4-(5H)-one derivatives acting as protein tyrosine kinase (EGFR) inhibitors. The study has been carried out using VLife MDS 4.6.1 software. The stepwise 3D-QSAR kNN-MFA method was applied to derive QSAR model. The information rendered by 3D-QSAR model may lead to a better understanding and designing of novel EGFR inhibitor molecules. 3D-QSAR is an important tool in understanding the structural requirements for design of novel, potent and selective EGFR inhibitors. Thus, the present work can be employed for new drug discovery and can be used in future for designing novel derivatives of pyrazolothiazol-4-(5H)-one with higher EGFR inhibitory activity.
Keyword: EGFR inhibitors, stepwise 3D-QSAR, kNN-MFA model, pyrazolothiazol-4-(5H)-one derivatives.
Download: Request For Article
 












USER LOGIN


Username
Password
Login | Register
AICTE INTERNATIONAL CONFERENCE

AICTE Sponsored International Conference on Challenges, Opportunities and Newer Directions of Pharmacovigilance and Clinical Research in India

Download Brochure


For More Detail Visit www.pippharmacon.org
News & Events
SCImago Journal & Country Rank
hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477